Table 1. Characteristic of Individuals Analyzed and Total Antibodies to the SARS-CoV-2 Spike (S) Protein Receptor Binding Domain (RBD) Response After Complete BNT162b2 Vaccination.
| Total | Males | Females | < 35 years | > 35 years | |
|---|---|---|---|---|---|
| N | |||||
| All | 297 | 108 | 189 | 108 | 189 |
| VAX+/- | 165/132 | 63/45 | 102/87 | 65/43 | 100/89 |
| Age | |||||
| All | 42 ± 0.8 | 44 ± 1.5 | 40 ± 1.0 | 25 ± 0.5 | 50 ± 0.6 |
| P | 0.014 | ||||
| VAX+/- | 41 ± 1.1/42 ± 1.1 | 44 ± 2.1/44 ± 1.9 | 39 ± 1.3/41 ± 1.4 | 24 ± 0.5/26 ± 0.7 | 51 ± 0.8/49 ± 0.8 |
| P | 0.473 | 0.791 | 0.382 | 0.027 | 0.130 |
| BMI | |||||
| All | 24.2 ± 0.2 | 25.2 ± 0.3 | 23.8 ± 0.3 | 22.9 ± 0.3 | 25.1 ± 0.3 |
| P | 0.005 | < 0.001 | |||
| VAX+/- | 23.8 ± 0.3/24.9 ± 0.4 | 24.8 ± 0.3/25.7 ± 0.5 | 23.2 ± 0.4/24.4 ± 0.5 | 22.5 ± 0.3/23.1 ± 0.5 | 24.7 ± 0.4/25.6 ± 0.5 |
| P | 0.0257 | 0.0925 | 0.0831 | 0.1692 | 0.1436 |
| Anti-spike-RBD (BAU/mL) | |||||
| All | 1795.5 ± 97.6 | 1,727.7 ± 159.3 | 1,834.6 ± 124.0 | 2,184.8 ± 152.7 | 1,590.9 ± 124.6 |
| P | 0.598 | 0.0038 | |||
| VAX+/- | 2,047.4 ± 139.9/1,494.2 ± 129.6 | 2,090.8 ± 249.8/1,304.1 ± 148.2 | 2,041.1 ± 168.5/1,592.5 ± 181.6 | 2,339.6 ± 190.4/1,959.7 ± 253.9 | 1,874.6 ± 196.1/1,261.5 ± 142.9 |
| P | 0.0039 | 0.0144 | 0.0705 | 0.2479 | 0.0124 |
Patients with relevant comorbidity (including diabetes, hypertension, dyslipidemia, kidney disease or cancer) as well as smokers/drinkers subjects have been excluded. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; VAX+: individuals vaccinated for seasonal influenza; VAX-: individuals not vaccinated for seasonal influenza; BMI: body mass index; RBD: receptor binding domain; BAU: binding antibody unit.